GlaxoSmithKline Biologicals, Belgium
Pfizer, USA
Merck, USA
Novartis AG, Switzerland
Sanofi Pasteur, France
Sanofi-Aventis, France
MedImmune, USA
Baxter, USA
Novozymes A/S, Denmark
Wyeth, USA
Intercell, Austria
Crucell, Netherlands
VaxInnate, Inc., USA
Shenzhen Polytechnic, China
Medicago Inc, Canada
Novartis Vaccines, USA
Cyto Pulse Sciences, Inc., USA
GlaxoSmithKline Biologicals, USA
Selecta Biosciences Inc., USA
Petrovax Group, Russia
Becton,Dickinson&Company, USA
TechnoVax, USA
Antagen Biosciences, Inc., USA
Apogee Technology, Inc, USA
Acambis, UK
Chiron, USA
3M, USA
CSC, USA
AlphaVax, USA
Emergent BioSolutions, UK
Hawaii Biotech, USA
Arbovax, Inc, USA
PATH, USA
Sigma-Aldrich, USA
Duke-NUS, Singapore
TechnoVax, Inc., USA
Medicago Inc, Canada
Kotwal Bioconsulting, LLC, USA
MedImmune Vaccine, USA
Synergy America, Inc., USA
VPM Inc., Germany
Shanghai H&G Biotechnology Inc., China
Oxford-Emergent Tuberculosis Consortium Ltd, UK
Theraclone Sciences, Inc, USA
Green Cross Therapeutics Pvt Ltd, India
DanDrit Biotech, Denmark
Crossbeta Biosciences B.V., The Netherlands
Transgene S.A., France
TD Consultancy, LLC, USA
BioReliance, UK
Biosante Pharmaceuticals, USA
Vaxgen Corporation, USA
AXIO International, France
Charles River Avian Products and Services, USA
Strategic Manufacturing Worldwide, Inc., USA
GE Healthcare Life Sciences, Sweden
VTI Pharmaceutical Technologies (Shenzhen) Co., Ltd., China
GE Healthcare Life Sciences,China
Althea Technologies Inc., USA
immatics biotechnologies GmbH,Germany
Green Hills Biotechnology GmbH, Austria
Gan Shmuel, Israel
SIOGEN Biotech, Malaysia
OptiNose AS, Norway
Civimetrix, Canada
Apotex, Canada
Biovet Pvt Ltd, India
BD Technologies,



International Vaccine Institute
International AIDS Vaccine Institute
Global TB Vaccine Foundation
Bill & Melinda Gates Foundation, USA
Center for Disease Control and Prevention, China
Center for Disease Control and Prevention, USA
Children’s Global Health Initiative, USA
Vaccine and Infectious Disease Organization, Canada
Sabin Vaccine Institute, USA
National Institutes of Health , USA
National Human Genome Research, USA
National Vaccine and Serum Institute, China
Karolinska Institute, Sweden
Anderson Cancer Center, USA
Albert Einstein College of Medicine, USA
Oxford University, UK
Institute Pasteur, France
Tufts University, USA
Tufts University School of Medicine, USA
Fudan University, China
University of Missouri-Columbia, USA
Aarhus University Hospital – Skejby, Denmark
Baylor College of Medicine, USA
Fraunhofer USA CMB, USA
INSERM, France
Arizona State University, USA
Uppsala University. Sweden
US Army Medical Research Institute of Infectious Diseases, USA
Arizona State University, USA
University of Calgary, Canada
Gold Coast Campus, Australia
University of Calgary, Canada
National Health Research Institutes,Taiwan
Netherlands Vaccine Institute, Netherlands
Chungnam National University, Korea
The University of Sydney, Australia
Queen Mary University of London, UK
University of Lille2 and University of Artois, France
Ghent University, Belgium
Chicago Medical School, USA
National University of Colombia, Colombia
Army Medical Research Institute of Infectious Diseases, USA
European Commission Joint Research Center, Italy
University of Arkansas for Medical Sciences, USA
Mount Sinai School of Medicine, USA
University of New South Wales, Australia
Chinese Academy of Engineering, China
CrucellBerna Biotech Korea, Korea
Pomeranian Medical University, Poland
Public Health Service, The Netherlands
University of New South Wales, Australia
The Wistar Institute, USA
Kamineni Institute of Medical Sciences, India
RMIT University, Australia
National Taiwan University, Taiwan
University of Indonesia, Indonesia
World Health Organization, Switzerland
Russian Academy of Medical Sciences,Russian Federation
National Tsing Hua University, Taiwan
University of California, Davis, USA
Kuwait University, Kuwait
Lanzhou University, China
Texas Tech University Health Sciences Center, USA
Queensland Institute of Medical Research, Australia
French National Academy of Medicine, France
New York University, USA
Harvard Medical School, USA
Link?ping University, Sweden
D Cotugno Hospital, Italy
Chiang Mai University, Thailand
The Ohio State University, USA
Deakin University, Australia.
Vrije Universiteit Brussel, Belgium
University of Paris, France
University of Southampton, UK
University of Ulm, Germany
National Cancer Research Center, Serbia
World Health Organisation (WHO), Uganda
Cornell University, USA
Hacettepe University, Turkey
Tel Aviv University, Israe
National Institute of Hygiene, Morocco


 Schedule

Program Schedule

Time: March 24-26, 2010; Conference Place: International Convention Center (ICC)-Continental Grand Hotel (CGH), Beijing, China

Time

Program

Place

March 23, 2010 (Tuesday)

Registration

3F, ICC

08:00-20:00

March 24, 2010 (Wednesday)

Group Photo

3F, ICC

08:20-08:40

March 24, 2010 (Wednesday)

Opening Ceremony

No.3 Conference Room, 1F, ICC

09:00-09:35

March 24, 2010 (Wednesday)

Keynote Forum

09:40-12:10

March 24, 2010 (Wednesday)

Welcome Banquet and Art Performance

Banquet Hall, 2F, CGH

18:30-20:00

March 24, 2010
Wednesday
p.m.

13:30-14:30

Track 1-1: Infectious Immunology, Immunity and Vaccinology

No. 311A Conference Room, 3F, ICC

14:30-15:10

Track 1-2: Advanced Cell Biology and Molecular Biology in Vaccine Development

15:30-17:30

Track 1-3: Novel Technologies for Antigen Discovery and Vaccine Development

13:30-15:55

Track 2-1: Hepatitis Vaccines

No. 311B Conference Room, 3F, ICC

15:55-16:20

Track 2-2: Herpes Virus and Measles Vaccines

13:30-16:20

Track 6-1: Safety Evaluation of Vaccines

No. 311C Conference Room, 3F, ICC

16:20-16:45

Track 6-2: Regulatory Issues, Standards and Quality Control over Vaccines

March 25, 2010 Thursday

08:10-10:10

Track 1-4: DNA Vaccine Technologies

No. 311A Conference Room, 3F, ICC

08:30-11:45

Track 1-5: Adjuvants and Vaccine Designs (part I )

No. 311B Conference Room, 3F, ICC

10:00-11:40

Track 1-6: Innate Immunity, Mucosal Immunity and Novel Vaccines

No. 309 Conference Room, 3F, ICC

08:30-09:20

Track 2-3: Gastrointestinal Infection Vaccines

No. 311C Conference Room, 3F, ICC

09:40-12:10

Track 2-4: HPV Vaccine to Gynecological Vaccines

11:45-12:10

Track 3-1: Epidemiology, Prevention Research, and Economic Sciences

No. 311B Conference Room, 3F, ICC

08:30-09:45

Track 3-2: Innate Immunity, Dendritic Cells, and T Cell Immunity

No. 309 Conference Room, 3F, ICC

10:30-11:50

Track 4: Human Vaccines: Non-Infectious Diseases

No. 311A Conference Room, 3F, ICC

08:30-12:10

Track 8-1: Better Tools for Bioprocessing Vaccines

No. 310 Conference Room, 3F, ICC

12:00-13:00

Luncheon

Banquet Hall, 2F, CGH

16:20-17:10

Track 1-7: Cytokine Networks in Vaccine Designs

No. 310 Conference Room, 3F, ICC

13:30-16:20

Track 1-8: Novel Vaccine Delivery Technologies

13:30-16:50

Track 1-9: Adjuvants and Vaccine Designspart II

No. 311A Conference Room, 3F, ICC

14:40-17:35

Track 2-5: Flaviviruses Vaccines-Caliciviruses, Dengue and Japanese Encephalitis

No. 311B Conference Room, 3F, ICC

13:30-14:20

Track 2-6: Diarrhoeal Disease Vaccines-Enterotoxigenic Escherichia coli, Rotavirus, Shigellosis and Typhoid

15:00-16:00

Track 3-3: Neutralizing Antibodies and Immune Escape

No. 309 Conference Room, 3F, ICC

13:30-14:50

Track 3-4: Validation of Animal Models and Clinical Trials on AIDS Vaccines

16:00-17:20

Track 3-5: Novel AIDS Vectors and Immunogen

16:00-17:20

Track 6-3: Public Health and New Vaccines Developed in Asia and other Developing Countries

No. 311C Conference Room, 3F, ICC

13:30-14:30

Track 6-4: Vaccines against Bioterrorism

14:40-16:00

Track 6-5: Milestone Review on Global Vaccination Projects

March 26, 2010
Friday

08:30-11:10

Track 2-7: Influenza Vaccines

No. 310 Conference Room, 3F, ICC

11:10-11:50

Track 2-8: Vaccines on Avian Flu

08:30-10:10

Track 5-1: Cancer Epidemiology, Tumor Immunology, and Immunotherapy

No. 311A Conference Room, 3F, ICC

10:30-11:20

Track 5-2: New Cancer Vaccine Discovery Technologies for Targetable Antigens

08:30-11:10

Track 7-1: Veterinary Immunity and Vaccine Development

No. 311B Conference Room, 3F, ICC

11:10-12:10

Track 7-2: Livestock Vaccines

08:30-10:35

Track 7-3: Aquaculture Vaccines

No. 311C Conference Room, 3F, ICC

12:00-13:00

Luncheon

Banquet Hall, 2F, CGH

16:40-17:40

Track 2-9: Vaccines on Swine Flu

No. 310 Conference Room, 3F, ICC

15:30-17:10

Track 2-10: Pneumococcus and Respiratory Syncytial Virus

No. 311A Conference Room, 3F, ICC

13:30-17:10

Track 2-11: Malaria and Tuberculosis Vaccines

No. 311B Conference Room, 3F, ICC

13:30-15:10

Track 2-12: Parasitic Disease Vaccines-Hookworm, Leishmaniasis, Schistosomiasis

No. 310 Conference Room, 3F, ICC

15:30-16:30

Track 2-13: Other Infectious Diseases
-Bacteria: Buruli Ulcer, Leptospirosis, Neisseria Meningitidis, Streptococcus Group A/B, Trachoma
-Emerging Virus: Rubella, West Nile Fever, SARS, Ebla Virus, Prion Toxins

13:30-15:10

Track 5-3: Dendritic Cell based Cancer Vaccines

No. 311C Conference Room, 3F, ICC

15:30-17:30

Track 5-4: Vaccine Approaches to Immunotherapy and Clinical Trials

13:30-14:45

Track 8-2: Creating Safe, Reliable, High Yield Platforms for the Expression of Vaccine Antigens

No. 311A Conference Room, 3F, ICC

14:45-15:10

Track 8-3: Robust Bioprocessing of DNA Vaccines

03/27-03/31/2010

Tech Tour

Beijing & Xi’ an

 

 
© 2009-2010 All right reserved for BIT Conferences
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84799629